GastroAGI Logo
OverviewBlogsAbout
Trending TopicsConference
Topics/Small and Large Bowel/Auto-Brewery Syndrome (ABS)

Auto-Brewery Syndrome (ABS)

Clinical knowledge base curated and reviewed by GastroAGI TeamLast updated August 1, 2025

Quick Answer

**Auto-Brewery Syndrome (ABS)**, also referred to as **gut fermentation syndrome**, is a rare and likely underdiagnosed medical condition in which gut microbes (bacteria and/or yeast) ferment carbohydrates into ethanol (alcohol) within the gastrointestinal tract. This leads to elevated blood alcohol levels, causing symptoms of intoxication even when the individual has not consumed any alcoholic beverages.


**Auto-Brewery Syndrome (ABS)**, also referred to as **gut fermentation syndrome**, is a rare and likely underdiagnosed medical condition in which gut microbes (bacteria and/or yeast) ferment carbohydrates into ethanol (alcohol) within the gastrointestinal tract. This leads to elevated blood alcohol levels, causing symptoms of intoxication even when the individual has not consumed any alcoholic beverages.

### **Key Features of Auto-Brewery Syndrome (ABS):**

#### **Symptoms:**

  • **Intoxication-like effects** without alcohol consumption:
  • Slurred speech
  • Dizziness
  • Poor coordination
  • Cognitive impairment
  • **Brain fog** and difficulty concentrating
  • Fatigue
  • Social, legal, or professional issues similar to those faced by individuals with alcohol use disorder (e.g., DUI charges or workplace concerns)
  • Potential mood changes, irritability, or confusion

#### **Underlying Cause:**

The condition is caused by an overgrowth of ethanol-producing microbes in the gut. These microbes ferment dietary carbohydrates (like sugar or starch) into alcohol. The most commonly implicated organisms include:

  • **Klebsiella pneumoniae**
  • **Escherichia coli (E. coli)**
  • Occasionally, certain **yeast species** (e.g., *Saccharomyces cerevisiae*, also known as brewer's yeast)

#### **Diagnosis:**

Diagnosis of ABS is challenging and often delayed due to its rarity and the nonspecific nature of its symptoms. The following diagnostic tools are used:

1. **Oral Glucose Challenge Test**:

  • The patient consumes a glucose-rich solution, and blood alcohol levels are monitored over time.
  • A rise in blood alcohol levels above the legal driving limit (without alcohol consumption) confirms gut-driven ethanol production.

2. **Stool Analysis**:

  • Stool samples are analyzed to identify ethanol-producing microbes, such as *Klebsiella pneumoniae* or *E. coli*.
  • Studies of fermentation pathways may reveal heightened microbial activity leading to excess ethanol production.

3. **Blood Alcohol Testing**:

  • Elevated blood alcohol levels in the absence of alcohol ingestion provide critical evidence.

#### **Treatment Options:**

Treatment for ABS focuses on reducing the overgrowth of ethanol-producing microbes and restoring gut microbial balance. Approaches include:

1. **Selective Antibiotics**:

  • Used to target and reduce overgrowth of specific ethanol-producing bacteria like *Klebsiella pneumoniae* or *E. coli*.

2. **Probiotics and Prebiotics**:

  • Probiotics (beneficial bacteria) and prebiotics (compounds that promote the growth of healthy gut microbes) may help restore a balanced gut microbiome.

3. **Antifungal Medications**:

  • If yeast (e.g., *Saccharomyces cerevisiae*) is involved, antifungal drugs may be prescribed.

4. **Dietary Modifications**:

  • Reducing carbohydrate and sugar intake can limit the substrate available for fermentation by gut microbes.

5. **Fecal Microbiota Transplant (FMT)**:

  • A promising treatment in which healthy donor stool is transplanted to the patient to restore a balanced gut microbiome.
  • One patient in a recent study achieved long-term remission after repeated FMT treatments.

#### **Recent Research and Findings:**

  • In a 2019 case, *Klebsiella pneumoniae* was identified as a major cause of ABS in one patient.
  • Dr. Bernd Schnabl from UC San Diego created the largest cohort of ABS patients to date, studying 22 individuals with confirmed cases.
  • Stool studies revealed that *E. coli* and *Klebsiella pneumoniae* were the primary ethanol-producing microbes, with heightened fermentation pathways during symptom flares.

#### **Prevalence and Underdiagnosis:**

Although ABS is still considered rare, it may be more common than currently recognized. Many patients may have mild symptoms, such as fatigue or brain fog, which are often attributed to other conditions. Physicians are encouraged to consider ABS in cases of unexplained intoxication or cognitive symptoms, especially when blood alcohol levels are inexplicably elevated.

### **Key Takeaways:**

  • Auto-Brewery Syndrome is a condition where gut microbes produce alcohol, leading to symptoms of intoxication without alcohol consumption.
  • Diagnosis involves glucose challenge tests, blood alcohol testing, and stool analysis for ethanol-producing microbes.
  • Treatments include antibiotics, probiotics, dietary changes, antifungals, and fecal microbiota transplants.
  • While rare, ABS may be underdiagnosed, and awareness among healthcare providers is crucial for timely identification and management.

Related Q&A

Anal High-Grade Squamous Intraepithelial Lesions (HSIL): BJS | March 2026

Introduction: Anal squamous cell carcinoma is an increasingly common but largely preventable cancer. Most cases arise from persistent high-risk human papillomavirus (HPV) infection, progressing through high-grade squamous intraepithelial lesions (HSIL). This comprehensive review summarizes the...

Post-Infection DGBI (PI-DGBI): Gut | July 2026

Introduction: Acute infectious gastroenteritis can trigger persistent gastrointestinal symptoms long after the infection has resolved, leading to post-infection disorders of gut-brain interaction (PI-DGBI). This global Rome Foundation study evaluated the prevalence, risk factors, and clinical...

FMT in IBS: Gastroenterology | July 2026

Introduction: Gut microbiota alterations have been implicated in the pathogenesis of irritable bowel syndrome (IBS), making fecal microbiota transplantation (FMT) a promising therapeutic strategy. However, clinical trials have reported conflicting results. This updated meta-analysis evaluated...

Laparoscopic vs Open Adhesiolysis for Bowel Obstruction: JAMA Surgery | June 2026

Introduction: Laparoscopic adhesiolysis offers several short-term advantages over open surgery for adhesive small bowel obstruction (ASBO). However, its long-term impact on recurrence, quality of life, and incisional hernia remains uncertain. The LASSO trial provides the...

DPP-4 Inhibition Targets the Gut–Brain Axis in Parkinson's Disease: Gut | July 2026

Introduction: Growing evidence suggests that Parkinson's disease (PD) may originate in the gut, with pathological α-synuclein spreading to the brain through the vagus nerve. This study investigated whether sitagliptin, a widely used DPP-4 inhibitor for...

Bedside Ultrasound Outperforms Abdominal X-Ray in Neonatal Necrotizing Enterocolitis: Frontiers in Pediatrics | July 2026

Introduction: Necrotizing enterocolitis (NEC) is one of the most serious gastrointestinal emergencies in neonates. Early identification of infants requiring surgical intervention is critical but remains challenging. This study compared bedside abdominal ultrasonography (US) with abdominal...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer